According to a new study, cannabinoids CBC (cannabichromene) and CBG (cannabigerol) both exhibit anti-tumor properties, tested on human gastrointestinal cancer cells.

CBC and CBG were both shown to induce significantly higher rates of necrosis in GI cancer cells compared to other cannabinoids, thus strengthening previously obtained results.

See the original article on Cannabis Business Times